BR9815602A - Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer - Google Patents

Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer

Info

Publication number
BR9815602A
BR9815602A BR9815602-0A BR9815602A BR9815602A BR 9815602 A BR9815602 A BR 9815602A BR 9815602 A BR9815602 A BR 9815602A BR 9815602 A BR9815602 A BR 9815602A
Authority
BR
Brazil
Prior art keywords
composition
dna
animal
sensitive cells
response
Prior art date
Application number
BR9815602-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Inc filed Critical Bioniche Inc
Publication of BR9815602A publication Critical patent/BR9815602A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9815602-0A 1997-08-05 1998-08-05 Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer BR9815602A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US8631798P 1998-05-21 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Publications (1)

Publication Number Publication Date
BR9815602A true BR9815602A (pt) 2001-12-11

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815602-0A BR9815602A (pt) 1997-08-05 1998-08-05 Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
ES2238780T3 (es) * 1998-02-18 2005-09-01 Bioniche Life Sciences Inc. Tratamiento de cancer de vejiga mediante pared celular de mycobacterium phlei.
DE69920506T2 (de) * 1998-12-04 2005-10-13 Bioniche Life Sciences Inc., London Chemotherapeutische zusammensetzung und verfahren
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
EP1135164B1 (en) * 1998-12-04 2004-08-11 Bioniche Life Sciences Inc. Composition for the treatment of inflammation
ES2238996T3 (es) * 1999-04-01 2005-09-16 Bioniche Life Sciences Inc. Composicion y metodo para inducir apoptosis en celulas de cancer de prostata.
US6794368B1 (en) * 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
AR083443A1 (es) 2010-10-13 2013-02-27 Bioniche Life Sciences Inc Una composicion que comprende arn bacteriano y paredes celulares bacterianas, metodo para elaborar dicha composicion y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
BR9406496A (pt) 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death

Also Published As

Publication number Publication date
NZ502674A (en) 2002-06-28
WO1999007383B1 (en) 1999-03-25
KR100533576B1 (ko) 2005-12-05
AU8723698A (en) 1999-03-01
NO20000576L (no) 2000-04-04
IL134371A (en) 2007-07-24
JP2001513504A (ja) 2001-09-04
IL134371A0 (en) 2001-04-30
DK1003525T3 (da) 2003-03-24
ATE227996T1 (de) 2002-12-15
IL180924A (en) 2010-11-30
CA2299548A1 (en) 1999-02-18
US6329347B1 (en) 2001-12-11
HUP0003012A2 (hu) 2000-12-28
JP2008208140A (ja) 2008-09-11
CA2299548C (en) 2009-12-29
NO20000576D0 (no) 2000-02-04
AU736450B2 (en) 2001-07-26
WO1999007383A1 (en) 1999-02-18
JP4335435B2 (ja) 2009-09-30
EP1003525A1 (en) 2000-05-31
NO322450B1 (no) 2006-10-09
HU227921B1 (hu) 2012-06-28
ES2187047T3 (es) 2003-05-16
HUP0003012A3 (en) 2004-03-29
DE69809561D1 (de) 2003-01-02
PT1003525E (pt) 2003-03-31
EP1003525B1 (en) 2002-11-20
DE69809561T2 (de) 2003-09-25
IL180924A0 (en) 2007-07-04
US6326357B1 (en) 2001-12-04
KR20010022643A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
BR9815602A (pt) Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
MXPA03000014A (es) Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
WO2004000094A3 (en) Predictive markers in cancer therapy
NO20014537D0 (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
Zilberstein et al. Surface analysis of ancient parchments via the EVA film: The Aleppo Codex
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
Suzuki et al. Anthraquinone derivatives as a new family of protein photocleavers
Warren et al. Synthesis and Structural Characterization of the N2G− Mitomycin C− N2G Interstrand Cross-Link in a Model Synthetic 23 Base Pair Oligonucleotide DNA Duplex
AU2672099A (en) Compositions and methods for wound healing
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE69732857D1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
WO2003098223A3 (en) A method for killing cells by inhibiting histone activity in the cell
ES2073165T3 (es) Metodos y composiciones para el tratamiento de enfermedades malignas a las que esta asociada una proteina quinasa.
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
Seyedin et al. H1 histones of trout.
ATE376840T1 (de) Gentherapeutika
Kudo et al. Auditory projections from the IC to the SCN by way of the LG in the mole, Mogera

Legal Events

Date Code Title Description
TCP Change of proprietor's name pending
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/711 (2008.01), A61K 35/74 (2008.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO ESTABELECIDO PELOS ARTIGOS 8O E 13 E 25 DA LPI ( LEI 9279/96 )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BIONICHE LIFE SCIENCES, INC. (CA)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]